Downstream Processing of an Alkaline Phosphatase

Abstract

The invention relates to the field of downstream processing (DSP) of an alkaline phosphatase (AP). More specifically, it relates to a method for reducing host cell protein content in a composition comprising AP. The invention further relates to a composition comprising an AP and a reduced content of a host cell protein.

1 . A method for isolating an alkaline phosphatase (AP) comprising:
 (a) providing a solid phase comprising a ligand of formula (I):   
       
         
           
           
               
               
           
         
         wherein R is a spacer molecule which links the ligand to the solid phase, 
         (b) contacting said ligand with a composition comprising an AP that comprises an amino acid sequence at least 90% identical to SEQ ID NO: 1 and a host cell protein (HCP); 
         (c) performing two or more wash steps, wherein at least one wash step is performed using a wash buffer comprising between 20-100 mM arginine (Arg), between 0.5-2 M Urea, or between 5-15% ethylene glycol, or any combination thereof; and 
         (d) eluting said AP from the ligand with an elution buffer; 
         wherein said eluate comprises less than 100 ppm HCP. 
       
     
     
         2 . The method according to  claim 1 , wherein the wash buffer comprises less than 1 mM NaCl. 
     
     
         3 . The method according to  claim 1 , wherein the elution buffer comprises less than 1 mM NaCl. 
     
     
         4 . The method according to  claim 1 , wherein the washing buffer comprises about 40 mM Arg. 
     
     
         5 . The method according to  claim 1 , the method further comprising:
 (i) providing a second solid phase comprising a second ligand of formula (II):   
       
         
           
           
               
               
           
         
         (ii) contacting said second ligand with a composition comprising said AP and a HCP, and 
         (iii) performing two or more wash steps, wherein at least one wash step is performed using a second washing buffer having a pH between 7.5-8.5 and comprising between 0.05-0.2 M NaCl and between 0.1-0.5 M L-Arg. 
       
     
     
         6 . The method according to  claim 5 , wherein said second washing buffer comprises between 1-20% glycerol. 
     
     
         7 . The method according to  claim 5 , wherein (i)-(ii) precedes (a)-(d). 
     
     
         8 . The method according to  claim 1 , further comprising at least one further purification step selected from the group consisting of anion exchange chromatography, ultrafiltration/diafiltration, viral filtration, and hydrophobic interaction chromatography, and any combination thereof. 
     
     
         9 . A method for producing a composition comprising an isolated alkaline phosphatase (AP), the method comprising
 dissolving or diluting said AP in a buffer, which results in a composition having a pH of between 6.5 and 7.5 and comprising between 200-300 mM sorbitol, and/or between 10-40% glycerol, and/or between 5-40 mM histidine, and/or between 10-40 mM citrate, or any combination thereof;   wherein there is no visible particle formation in said composition, using a stability test at 2-8° C. for 2 months.   
     
     
         10 . The method according to  claim 9 , wherein the composition comprises less than 100 ppm host cell protein (HCP). 
     
     
         11 . A composition comprising an isolated alkaline phosphatase, wherein the composition comprises less than 100 ppm of a host cell protein (HCP) and wherein the composition does not show visible particle formation during stability testing at 2-8° C. for 2 months. 
     
     
         12 . The composition according to  claim 11 , wherein the composition has a pH of between 6.5-7.5, and comprises between 10-40 mM citrate or between 5-40 mM histidine. 
     
     
         13 . The composition according to  claim 12 , wherein the composition comprises between 200-300 mM sorbitol and/or between 10-40% glycerol. 
     
     
         14 . The method according to  claim 1 , wherein the alkaline phosphatase comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 1. 
     
     
         15 . The method according to  claim 1 , wherein the HCP is a cathepsin-like protein and/or wherein said alkaline phosphatase is obtained from a cell-based expression system. 
     
     
         16 . The method for treating a disease or condition that can be improved by the administration of alkaline phosphatase, the method comprising administering to an individual in need thereof the composition according to  claim 11 . 
     
     
         17 . The method according to  claim 10 , wherein the composition comprises AP obtained by a method comprising:
 (a) providing a solid phase comprising a ligand of formula (I):   
       
         
           
           
               
               
           
         
         wherein R is a spacer molecule which links the ligand to the solid phase, 
         (b) contacting said ligand with a composition comprising an AP that comprises an amino acid sequence at least 90% identical to SEQ ID NO: 1 and a host cell protein (HCP); 
         (c) performing two or more wash steps, wherein at least one wash step is performed using a wash buffer comprising between 20-100 mM arginine (Arg), between 0.5-2 M Urea, or between 5-15% ethylene glycol, or any combination thereof; and 
         (d) eluting said AP from the ligand with an elution buffer; 
         wherein said eluate comprises less than 100 ppm HCP. 
       
     
     
         18 . The composition according to  claim 11 , wherein the alkaline phosphatase comprises an amino acid sequence that is at least 95% identical to SEQ ID NO: 1. 
     
     
         19 . The composition according to  claim 11 , wherein the HCP is a cathepsin-like protein and/or wherein said alkaline phosphatase is obtained from a cell-based expression system.